Results 11 to 20 of about 13,502,816 (309)

Irreproducibility –The deadly sin of preclinical research in drug development [PDF]

Journal of Pre-Clinical and Clinical Research, 2020
Introduction In recent years the irreproducibility of preclinical studies has become a serious concern in drug developmental research. The findings of preclinical studies that cannot be reproduced are a drain on public resources and slow down the drug ...
Sadasivan Kalathil Pillai, Katsumi Kobayashi, Mathews Michael, Meena Arumugam   +3 more
doaj   +2 more sources

Quality Standards of Preclinical Pharmacological Studies [PDF]

Регуляторные исследования и экспертиза лекарственных средств, 2019
The quality and effectiveness of preclinical trials of medicines depend on compliance with the Good Laboratory Practice (GLP) principles. At the same time, the data of the World Health Organisation (WHO) and the analysis of the regulatory framework ...
G. N. Engalycheva, R. D. Syubaev, D. V. Goryachev   +2 more
doaj   +2 more sources

Preclinical Studies of Low Back Pain

Molecular Pain, 2013
Chronic low back pain is a major cause of disability and health care costs. Current treatments are inadequate for many patients. A number of preclinical models have been developed that attempt to mimic aspects of clinical conditions that contribute to ...
Judith A Strong, Wenrui Xie, Feguens J Bataille, Jun-Ming Zhang   +3 more
doaj   +3 more sources

Preclinical Studies in the Pharmaceutical Development Cycle

Регуляторные исследования и экспертиза лекарственных средств
The ultimate goal of preclinical studies is to generate data that can be used to make conclusions about the potential effects of a new medicine on the human body and to properly proceed to clinical trials. In this interview, Marina N. Makarova, Doctor of
M. N. Makarova
doaj   +2 more sources

Vaccines with adjuvants. Preclinical studies [PDF]

Биопрепараты: Профилактика, диагностика, лечение, 2018
The paper presents the data on safety and efficacy assessment of adjuvants and vaccines with adjuvants at the stages of development and preclinical studies based on international recommendations.
Zh. I. Avdeeva, N. A. Alpatova, V. P. Bondarev, R. A. Volkova, N. I. Lonskaya, E. V. Lebedinskaya, N. V. Medunitsyn, A. N. Mironov, N. A. Ozeretskovsky, A. A. Soldatov, V. A. Shevtsov   +10 more
doaj   +1 more source

Clinical relevance assessment of animal preclinical research (RAA) tool: development and explanation. [PDF]

, 2021
Only a small proportion of preclinical research (research performed in animal models prior to clinical trials in humans) translates into clinical benefit in humans.
Gurusamy, KS, Barron, Carly C, McHugh, TD, Moher, D., Avey, MT, Osborne, N., Gluud, C, Barron, Carly C., Jell, G, van Laarhoven, Kees, Ahmed, Irfan, Moher, D, Loizidou, Marilena, Katakam, K, Loizidou, M., Ritskes-Hoitinga, Merel, Dwek, M, Lalu, Manoj, Laarhoven, K. van, Avey, M., Ritskes-Hoitinga, M., Katakam, Kiran, Montroy, Joshua, Moher, David, Ahmed, I, Gurusamy, K.S., Avey, Marc T., Barron, CC, Gurusamy, K., Davidson, B, Vollert, J, Loizidou, M, Jell, G., van Laarhoven, K, Dwek, M., Vollert, Jan, Ritskes-Hoitinga, M, Davidson, Brian, Osborne, NJ, Gluud, C., Montroy, J, Lalu, M, McHugh, T.   +42 more
core   +1 more source

Should Peak Dose Be Used to Prescribe Spatially Fractionated Radiation Therapy?—A Review of Preclinical Studies [PDF]

, 2022
SIMPLE SUMMARY: This review study analyzed preclinical studies available before 2022 on spatially fractionated radiation therapy (SFRT), a promising cancer therapy with a high therapeutic index. We intend to use the results of preclinical studies to shed
Prezado, Yolanda, Yolanda Prezado, Sha Chang, Fernandez-Palomo, Cristian, Chang, Sha, Cristian Fernandez-Palomo   +5 more
core   +2 more sources

In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice. [PDF]

, 2012
Xenograft mouse models represent helpful tools for preclinical studies on human tumors. For modeling the complexity of the human disease, primary tumor cells are by far superior to established cell lines.
zur Stadt, Udo, Groiss, Volker, Schneider, Katja, Renier J Brentjens, Nadia Terziyska, Harald Ehrhardt, Jeremias, I., Brentjens, Renier J., Farkasova, K., Katja Schneider, Volker Groiss (106787), Katarina Farkasova (106794), Ehrhardt, Harald, Wagner, E., Renier J. Brentjens (106801), Quintanilla-Martinez, Leticia, Martin Horstmann (45040), Ehrhardt, H., Ernst Wagner (60760), Wagner, Ernst, Leticia Quintanilla-Martinez (33277), Terziyska, N., Katja Schneider (106791), Horstmann, M., Brentjens, R.J., Catarina Castro Alves, Quintanilla-Martinez, L., Zur Stadt, U., Horstmann, Martin, Schneider, K., Ogris, M., Manfred Ogris, Alves, C.C., Nadia Terziyska (106777), Terziyska, Nadia, Jeremias, Irmela, Groiss, V., Irmela Jeremias (106806), Volker Groiss, Udo zur Stadt, Martin Horstmann, Farkasova, Katarina, Ernst Wagner, Irmela Jeremias, Ogris, Manfred, Udo zur Stadt (106803), Catarina Castro Alves (106783), Manfred Ogris (60759), Castro Alves, Catarina, Katarina Farkasova, Leticia Quintanilla-Martinez, Harald Ehrhardt (106798)   +51 more
core   +2 more sources

Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies [PDF]

, 2019
Irreproducibility of preclinical findings could be a significant barrier to the “bench-to-bedside” development of oncolytic viruses (OVs). A contributing factor is the incomplete and non-transparent reporting of study methodology and design.
Conic, Isidora, Leung, Garvin J, Lalu, Manoj M, Ilkow, Carolina, Wesch, Neil L, Presseau, Justin, Kimmelman, Jonathan, Cobey, Kelly D, Auer, Rebecca, Diallo, Jean-Simon, MacNeil, Jenna L, Krishnan, Ramya, Kekre, Natasha, El-Sayes, Nader, Keller, Brian A, Fergusson, Dean A   +15 more
core   +1 more source

Effectiveness of sacubitril-valsartan in patients with cancer therapy-related cardiac dysfunction (CTRCD): a systematic review of clinical and preclinical studies

, 2022
Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment.
Neto, Mansueto G, Tse, Gary, Biondi-Zoccai, Giuseppe, Mesquita, Evandro T, Roever, Leonardo, Chan, Jeffrey S, Duraes, Andre R, Liu, Tong, Bitar, Yasmin S, Boochi, Edimar A, Mesquita, Evandro T., Bocchi, Edimar A., de Souza Lima Bitar, Yasmin, Neto, Mansueto G., Chan, Jeffrey S., Duraes, Andre R., Andre R. DURAES, Evandro T. MESQUITA, Edimar A. BOCCHI, Tong LIU, Yasmin de SOUZA LIMA BITAR, Jeffrey S. CHAN, Giuseppe BIONDI-ZOCCAI, Gary TSE, Leonardo ROEVER, Mansueto G. NETO   +25 more
core   +1 more source